Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts less than Nifty Microcap 250 and 6.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore for FY2026, up ~10% from Rs 6,033 crore in the prior year. Standalone PAT grew 27% to Rs 640 crore, aided by a one-time deferred tax credit of Rs 100.27 crore from a Finance Act amendment. Operating margin expanded to 16.82% from 15.74% on the standalone basis. Exceptional items included Rs 48.64 crore for new Labour Code provisions (gratuity/compensated absences impact) and an Rs 18.35 crore write-down for the Sikkim manufacturing facility classified as held for sale. The Board recommended dividend of Rs 12 per share (600%), up from Rs 11 per share. Auditors KKC & Associates issued an unmodified opinion on both standalone and consolidated results. Consolidated revenue stood at Rs 7,345 crore with PAT of Rs 675 crore.
The 27% PAT growth and margin expansion are positive, though FY2026 PAT was significantly boosted by the Rs 100 crore deferred tax credit. Excluding this one-time benefit, underlying earnings growth is more modest. The Sikkim facility write-down and Labour Code charge are non-recurring but signal ongoing restructuring in manufacturing footprint.